1
|
Sotos-Prieto M, Delgado-Velandia M, Fernández-Felix BM, Zamora J, Ortolá R, García-Esquinas E, Rimm EB, Rodríguez-Artalejo F. Performance and validation of the Healthy Heart Score model for predicting 12-year cardiovascular mortality in a nationwide Mediterranean population. Rev Esp Cardiol (Engl Ed) 2023; 76:444-452. [PMID: 36379366 DOI: 10.1016/j.rec.2022.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 10/26/2022] [Indexed: 05/28/2023]
Abstract
INTRODUCTION AND OBJECTIVES The Healthy Heart Score (HHS) is a lifestyle-based equation for predicting cardiovascular disease (CVD) risk and may serve as a tool in primordial prevention. However, its performance outside North American populations is unknown. This study assessed the performance of the HHS for estimating CVD mortality in the adult population of Spain. METHODS We analyzed data from the ENRICA cohort, comprising 10 228 participants free of chronic disease and representative of the Spanish population aged ≥ 18-years, who were recruited from 2008 to 2010 and were followed up to 2020. The HHS includes body mass index, alcohol, physical activity, smoking, and a 5-component dietary score. The HHS was calculated at baseline using the sex-specific beta coefficients from the original development cohorts. Model discrimination was assessed using the Harrell c-statistic and Gonen-Heller c-statistic for survival data, and calibration was evaluated through calibration plots. RESULTS After a median follow-up of 11.8 years, 110 CVD deaths were ascertained. The discrimination of the HHS was similar for women (Harrell c, 0.91; 95%CI, 0.87-0.95; Gonen-Heller-c, 0.85; 95%CI, 0.83-0.88) and men (Harrell c, 0.91; 95%CI, 0.88-0.94; Gonen-Heller c: 0.85; 95%CI, 0.83-0.88). After recalibration by the sex-specific baseline survival function, the calibration became optimal for: a) all deciles of predicted CVD risk except the highest decile, where HHS underestimated the risk, and b) all age groups except 70 years and older, where there was an underestimation. CONCLUSIONS In this Spanish cohort, the HHS showed good discrimination and calibration for predicting CVD death. The performance of HHS in other European populations and its implementation in the clinical setting warrants further investigation.
Collapse
Affiliation(s)
- Mercedes Sotos-Prieto
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Instituto Madrileño de Estudios Avanzados - Alimentación (IMDEA-Food Institute), Campus de Excelencia Internacional de la Universidad Autónoma de Madrid y del Consejo Superior de Investigaciones Científicas (CEI UAM+CSIC), Madrid, Spain; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States.
| | - Mario Delgado-Velandia
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain
| | - Borja M Fernández-Felix
- Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Javier Zamora
- Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; World Health Organization (WHO) Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom
| | - Rosario Ortolá
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain
| | - Esther García-Esquinas
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain
| | - Eric B Rimm
- Department of Nutrition, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States; Channing Division of Network Medicine, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States
| | - Fernando Rodríguez-Artalejo
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain; Instituto Madrileño de Estudios Avanzados - Alimentación (IMDEA-Food Institute), Campus de Excelencia Internacional de la Universidad Autónoma de Madrid y del Consejo Superior de Investigaciones Científicas (CEI UAM+CSIC), Madrid, Spain
| |
Collapse
|
2
|
Sotos-Prieto M, Delgado-Velandia M, Fernández-Felix BM, Zamora J, Ortolá R, García-Esquinas E, Rimm EB, Rodríguez-Artalejo F. Rendimiento y validación del Test del Corazón Saludable para la predicción de mortalidad cardiovascular en población mediterránea a escala nacional. Rev Esp Cardiol 2023. [DOI: 10.1016/j.recesp.2022.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
|
3
|
Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernández-Felix BM, Oristrell G, Ródenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-González I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials 2022; 23:1037. [PMID: 36539800 PMCID: PMC9769015 DOI: 10.1186/s13063-022-06977-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 12/02/2022] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND The real impact of the degree of association (DoA) between endpoint components of a composite endpoint (CE) on sample size requirement (SSR) has not been explored. We estimate the impact of the DoA between death and acute myocardial infarction (AMI) on SSR of trials using use the CE of major adverse cardiac events (MACE). METHODS A systematic review and quantitative synthesis of trials that include MACE as the primary outcome through search strategies in MEDLINE and EMBASE electronic databases. We limited to articles published in journals indexed in the first quartile of the Cardiac & Cardiovascular Systems category (Journal Citation Reports, 2015-2020). The authors were contacted to estimate the DoA between death and AMI using joint probability and correlation. We analyzed the SSR variation using the DoA estimated from RCTs. RESULTS Sixty-three of 134 publications that reported event rates and the therapy effect in all component endpoints were included in the quantitative synthesis. The most frequent combination was death, AMI, and revascularization (n = 20; 31.8%). The correlation between death and AMI, estimated from 5 trials¸ oscillated between - 0.02 and 0.31. SSR varied from 14,602 in the scenario with the strongest correlation to 12,259 in the scenario with the weakest correlation; the relative impact was 16%. CONCLUSIONS The DoA between death and AMI is highly variable and may lead to a considerable SSR variation in a trial including MACE.
Collapse
Affiliation(s)
- Josep Ramon Marsal
- grid.430994.30000 0004 1763 0287Cardiovascular Epidemiology and Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Pg. Vall d’Hebron, 119-129, 08035 Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain
| | - Iratxe Urreta-Barallobre
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.432380.eBiodonostia Health Research Institute, Clinical Epidemiology, San Sebastián, Spain ,grid.414651.30000 0000 9920 5292Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain
| | - Marimar Ubeda-Carrillo
- grid.414651.30000 0000 9920 5292Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Library Service, San Sebastián, Spain
| | - Dimelza Osorio
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.411083.f0000 0001 0675 8654Health Services Research Group, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
| | - Blanca Lumbreras
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.26811.3c0000 0001 0586 4893Public Health Department, Miguel Hernandez University, Alicante, Spain
| | - David Lora
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.512044.60000 0004 7666 5367Health Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain ,grid.4795.f0000 0001 2157 7667Statistical Studies Department, Universidad Complutense de Madrid (UCM), Madrid, Spain
| | - Borja M. Fernández-Felix
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.411347.40000 0000 9248 5770Clinical Biostatistics Unit, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain
| | - Gerard Oristrell
- grid.411083.f0000 0001 0675 8654Cardiology Department, Vall d’Hebron University Hospital, Barcelona, Spain ,grid.512890.7CIBER Cadiovascular Diseases, Madrid, Spain
| | - Eduard Ródenas-Alesina
- grid.411083.f0000 0001 0675 8654Cardiology Department, Vall d’Hebron University Hospital, Barcelona, Spain
| | - Lorena Herrador
- grid.411083.f0000 0001 0675 8654Cardiology Department, Vall d’Hebron University Hospital, Barcelona, Spain
| | - Mónica Ballesteros
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.411083.f0000 0001 0675 8654Health Services Research Group, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
| | - Javier Zamora
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.411347.40000 0000 9248 5770Clinical Biostatistics Unit, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain ,grid.6572.60000 0004 1936 7486Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK
| | - Jose I. Pijoan
- grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain ,grid.411232.70000 0004 1767 5135Clinical Epidemiology Unit, Cruces University Hospital, Barakaldo, Spain ,grid.452310.1Biocruces-Bizkaia Health Research Institute, Barakaldo, Spain
| | - Aida Ribera
- grid.430994.30000 0004 1763 0287Cardiovascular Epidemiology and Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Pg. Vall d’Hebron, 119-129, 08035 Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain
| | - Ignacio Ferreira-González
- grid.430994.30000 0004 1763 0287Cardiovascular Epidemiology and Research Unit, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Pg. Vall d’Hebron, 119-129, 08035 Barcelona, Spain ,grid.466571.70000 0004 1756 6246CIBER Epidemiology and Public Health, Madrid, Spain
| |
Collapse
|
4
|
Varela Barca L, Fernández-Felix BM, Navas Elorza E, Mestres CA, Muñoz P, Cuerpo-Caballero G, Rodríguez-Abella H, Montejo-Baranda M, Rodríguez-Álvarez R, Gutiérrez Díez F, Goenaga MA, Quintana E, Ojeda-Burgos G, de Alarcón A, Vidal-Bonet L, Centella Hernández T, López-Menéndez J. Prognostic assessment of valvular surgery in active infective endocarditis: multicentric nationwide validation of a new score developed from a meta-analysis. Eur J Cardiothorac Surg 2021; 57:724-731. [PMID: 31782783 DOI: 10.1093/ejcts/ezz328] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 10/24/2019] [Accepted: 10/27/2019] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVES Several risk prediction models have been developed to estimate the risk of mortality after valve surgery for active infective endocarditis (IE), but few external validations have been conducted to assess their accuracy. We previously developed a systematic review and meta-analysis of the impact of IE-specific factors for the in-hospital mortality rate after IE valve surgery, whose obtained pooled estimations were the basis for the development of a new score (APORTEI). The aim of the present study was to assess its prognostic accuracy in a nationwide cohort. METHODS We analysed the prognostic utility of the APORTEI score using patient-level data from a multicentric national cohort. Patients who underwent surgery for active IE between 2008 and 2018 were included. Discrimination was evaluated using the area under the receiver operating characteristic curve, and the calibration was assessed using the calibration slope and the Hosmer-Lemeshow test. Agreement between the APORTEI and the EuroSCORE I was also analysed by Lin's concordance correlation coefficient (CCC), the Bland-Altman agreement analysis and a scatterplot graph. RESULTS The 11 variables that comprised the APORTEI score were analysed in the sample. The APORTEI score was calculated in 1338 patients. The overall observed surgical mortality rate was 25.56%. The score demonstrated adequate discrimination (area under the receiver operating characteristic curve = 0.75; 95% confidence interval 0.72-0.77) and calibration (calibration slope = 1.03; Hosmer-Lemeshow test P = 0.389). We found a lack of agreement between the APORTEI and EuroSCORE I (concordance correlation coefficient = 0.55). CONCLUSIONS The APORTEI score, developed from a systematic review and meta-analysis, showed an adequate estimation of the risk of mortality after IE valve surgery in a nationwide cohort.
Collapse
Affiliation(s)
- Laura Varela Barca
- Department of Cardiovascular Surgery, University Hospital Son Espases, Palma de Mallorca, Spain.,University of Alcalá de Henares, Madrid, Spain
| | - Borja M Fernández-Felix
- University of Alcalá de Henares, Madrid, Spain.,CIBER Epidemiology and Public Health (CIBERESP), Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain
| | | | - Carlos A Mestres
- Department of Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland
| | - Patricia Muñoz
- CIBER Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, Spain.,Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón-Instituto de Investigación Sanitaria Hospital Gregorio Marañón, Madrid, Spain.,Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | | | - Hugo Rodríguez-Abella
- Department of Cardiovascular Surgery, University Hospital Gregorio Marañón, Madrid, Spain
| | | | - Regino Rodríguez-Álvarez
- Department of Cardiovascular Surgery, University Hospital Marques de Valdecilla, Santander, Spain
| | | | | | - Eduard Quintana
- Department of Cardiovascular Surgery, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
| | | | - Arístides de Alarcón
- Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Infectious Diseases Research Group, Institute of Biomedicine of Seville (IBiS), University of Seville, CSIC, University Hospital Virgen del Rocío, Seville, Spain
| | - Laura Vidal-Bonet
- Department of Cardiovascular Surgery, University Hospital Son Espases, Palma de Mallorca, Spain
| | - Tomasa Centella Hernández
- University of Alcalá de Henares, Madrid, Spain.,Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Madrid, Spain
| | - Jose López-Menéndez
- University of Alcalá de Henares, Madrid, Spain.,Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Madrid, Spain
| | | |
Collapse
|
5
|
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Lancet HIV 2020; 7:e565-e573. [PMID: 32763219 DOI: 10.1016/s2352-3018(20)30202-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2019] [Revised: 04/22/2020] [Accepted: 04/24/2020] [Indexed: 01/21/2023]
Abstract
BACKGROUND A low CD4/CD8 ratio during antiretroviral therapy (ART) identifies people with heightened immunosenescence and increased risk of mortality. We aimed to assess the effects of integrase strand transfer inhibitor (INSTI)-based, protease inhibitor-based, or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART on long-term CD4/CD8 ratio recovery. METHODS This prospective cohort study included 13 026 individuals with HIV registered in the Spanish HIV Research Network (CoRIS) cohort recruited from 45 Spanish hospitals. We included HIV-positive people who started triple ART (two nucleoside reverse transcriptase inhibitors [NRTI] with a NNRTI, protease inhibitor, or INSTI) and had HIV RNA suppression within 48 weeks. We used piecewise linear mixed models adjusted for potential confounders to compare longitudinal changes in the CD4/CD8 ratio between people receiving three different types of ART. We used Cox proportional-hazard models to compare the times to CD4/CD8 normalisation between the treatment groups, using cutoff ratios of 0·4, 1·0, and 1·5. FINDINGS 6804 individuals contributing 37 149 persons-years and 37 680 observations were analysed; median follow-up was 49 months (IQR 22-89). INSTI-based ART was associated with greater CD4/CD8 gain (change per year compared with INSTI was coefficient -0·07 [95% CI -0·08 to -0·06] for NNRTI and was -0·08 [-0·09 to -0·08] for protease inhibitors). Differences were observed from the first year of therapy and were driven by changes in both CD4 and CD8 cell counts. Subanalyses at different time periods suggested that these differences were driven by changes during the first year of ART without significant differences in the adjusted CD4/CD8 ratio trajectories after the second year of ART (change per year compared with INSTI was coefficient -0·03 [95% CI -0·05 to -0·13] for NNRTI and was -0·06 [95% CI -0·08 to -0·04] for protease inhibitors). Although no differences in the time until CD4/CD8 normalisation at a cutoff ratio of no less than 0·4 were reported between any of the groups, compared with the INSTI group, both the NNRTI and protease inhibitor groups showed lower rates of normalisation at cutoff ratios of 1·0 or more (adjusted hazard ratio 0·80 [95% CI 0·72-0·89] for the NNRTI group and 0·79 [0·69-0·89] for the protease inhibitor group), and 1·5 or more (0·79 [0·65-0·95] for the NNRTI group and 0·78 [0·64-0·97] for the protease inhibitor group). No differences were found between the different integrases in the time until CD4/CD8 normalisation. Subanalyses adjusted for the backbone NRTIs and allowing observations after virological failure yielded similar results. INTERPRETATION This study provides new evidence that reinforces the positioning of INSTI-based therapies as a first choice and underlines the importance of analysing the effects of therapeutic interventions on biomarkers linked with morbidity and mortality beyond the plasma HIV RNA and the CD4 cell counts. FUNDING Spanish AIDS Research Network (Instituto de Salud Carlos III), European Development Regional Fund "A way to achieve Europe".
Collapse
Affiliation(s)
- Sergio Serrano-Villar
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain.
| | - Javier Martínez-Sanz
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - Raquel Ron
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - Alba Talavera-Rodríguez
- Bioinformatic Unit, Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - Borja M Fernández-Felix
- Biostatistics Unit, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain; CIBER Epidemiología y Salud Pública, Madrird, Spain
| | - Sabina Herrera
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - Alfonso Muriel
- Biostatistics Unit, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain; CIBER Epidemiología y Salud Pública, Madrird, Spain
| | - Francisco Fanjul
- Department of Infectious Diseases, Hospital Universitario Son Espases, Palma, Spain
| | - Joaquín Portilla
- Department of Internal Medicine, Hospital General Universitario de Alicante, Alicante, Spain
| | - Josefa Muñoz
- Department of Infectious Diseases, Hospital Universitario Basurto, Bilbao, Spain
| | - Concha Amador
- Infectious Disease Unit, Hospital de la Marina Baixa, Alicante, Spain
| | | | - María J Vivancos
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | - Santiago Moreno
- Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain
| | | |
Collapse
|
6
|
Varela L, Vidal L, Fernández-Felix BM, Ventosa G, Navas E, Hidalgo I, Rodríguez-Roda J, Sáez de Ibarra JI, López-Menéndez J. Estimación de la mortalidad quirúrgica de la endocarditis infecciosa: comparación de las diferentes escalas específicas de cálculo de riesgo. Cirugía Cardiovascular 2020. [DOI: 10.1016/j.circv.2020.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
7
|
Varela Barca L, Navas Elorza E, Fernández-Hidalgo N, Moya Mur JL, Muriel García A, Fernández-Felix BM, Miguelena Hycka J, Rodríguez-Roda J, López-Menéndez J. Correction to: Prognostic factors of mortality after surgery in infective endocarditis: systematic review and meta-analysis. Infection 2019; 47:897. [PMID: 31552602 DOI: 10.1007/s15010-019-01357-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The original version of this article unfortunately contained a mistake.
Collapse
Affiliation(s)
- Laura Varela Barca
- Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain.
| | | | | | - Jose Luis Moya Mur
- Department of Cardiology, University Hospital Ramon y Cajal, Madrid, Spain
| | | | - B M Fernández-Felix
- Clinical Biostatistics Unit, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain.,CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain
| | - Javier Miguelena Hycka
- Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain
| | - Jorge Rodríguez-Roda
- Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain
| | - Jose López-Menéndez
- Department of Cardiovascular Surgery, University Hospital Ramon y Cajal, Ctra. Colmenar Viejo, km. 9.100, 28034, Madrid, Spain
| |
Collapse
|